-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s two specifications of pitavastatin calcium tablets have been approved.
Category:
Time：2023-07-05
On July 4, Shijiazhuang No.4 Pharmaceutical Group obtained drug production registration approvals from the National Medical Products Administration for two specifications—1mg and 2mg—of Pivastatin Calcium Tablets, Class 4 chemical drugs, which are deemed to have passed the consistency evaluation. As of now, the Group has 52 varieties comprising 69 specifications that have either passed or been deemed to have passed the national generic drug quality and efficacy consistency evaluation.
On July 4, Shijiazhuang Fourth Pharmaceutical Group’s Class 4 chemical drug—Pitavastatin Calcium Tablets in two strengths, 1 mg and 2 mg—obtained the Drug Production Registration Approval from the National Medical Products Administration and is deemed to have passed the Consistency Evaluation. As of now, the Group has 52 varieties comprising 69 specifications of products that have either passed or been deemed to have passed the National Generic Drug Quality and Efficacy Consistency Evaluation.
It is reported that pitavastatin calcium tablets are primarily used for hypercholesterolemia and familial hypercholesterolemia.
Last May, the active pharmaceutical ingredient—pitavastatin calcium—developed and submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of the Group received approval from the National Medical Products Administration, allowing it to be officially used in marketed dosage forms. The approval of pitavastatin calcium tablets will play a positive role in further enriching and perfecting the product portfolio of this drug category, enhancing its market competitiveness, and accelerating the implementation of Shijiazhuang Fourth Pharmaceutical Group’s “API + Finished Dosage Form” strategy.
Keywords:
Previous
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license